Review of two immunosuppressants: tacrolimus and cyclosporine

키워드

참고문헌 (90)

1. Kirk AD, "Induction immunosuppression", Transplantation, 82, pp.593~602 (2006)[DOI]
2. Naesens M, "Calcineurin inhibitor nephrotoxicity", Clin J Am Soc Nephrol, 4, pp.481~508 (2009)[DOI]
3. Matsuda S, "Mechanisms of action of cyclosporine", Immunopharmacology, 47, pp.119~125 (2000)[DOI]
4. Walsh CT, "Cyclosporin A, the cyclophilin class of peptidylprolyl isomerases, and blockade of T cell signal transduction", J Biol Chem, 267, pp.13115~13118 (1992)
5. Ekberg H, "Reduced exposure to calcineurin inhibitors in renal transplantation", N Engl J Med, 357, pp.2562~2575 (2007)[DOI]
6. Ponticelli C, "Calcineurin inhibitors in renal transplantation still needed but in reduced doses : a review", Transplant Proc, 42, pp.2205~2208 (2010)[DOI]
7. Murthy MVR, "Cyclosporin-A production by Tolypocladium inflatum using solid state fermentation", Process Biochem, 34, pp.269~280 (1999)[DOI]
8. Corbett KM, "Cyclosporin structure and permeability : from A to Z and beyond", J Med Chem, 64, pp.13131~13151 (2021)[DOI]
9. Patel D, "Recent advances in cyclosporine drug delivery : challenges and opportunities", Drug Deliv Transl Res, 9, pp.1067~1081 (2019)[DOI]
10. Singh AK, "Cyclosporine : a commentary on brand versus generic formulation exchange", J Transplant, 2011, pp.480642~ (2011)[DOI]
11. Czogalla A, "Oral cyclosporine A--the current picture of its liposomal and other delivery systems", Cell Mol Biol Lett, 14, pp.139~152 (2009)[DOI]
12. Ritschel WA, "Microemulsion technology in the reformulation of cyclosporine : the reason behind the pharmacokinetic properties of Neoral", Clin Transplant, 10, pp.364~373 (1996)
13. Gelderblom H, "Cremophor EL : the drawbacks and advantages of vehicle selection for drug formulation", Eur J Cancer, 37, pp.1590~1598 (2001)[DOI]
14. Beauchesne PR, "Cyclosporine A : a review of current oral and intravenous delivery systems", Drug Dev Ind Pharm, 33, pp.211~220 (2007)[DOI]
15. Kino T, "FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics", J Antibiot(Tokyo), 40, pp.1249~1255 (1987)[DOI]
16. Zuo KJ, "Systemic and local FK506(tacrolimus)and its application in peripheral nerve surgery", J Hand Surg Am, 45, pp.759~765 (2020)[DOI]
17. Dheer D, "Tacrolimus : an updated review on delivering strategies for multifarious diseases", Eur J Pharm Sci, 114, pp.217~227 (2018)[DOI]
18. McCormack PL, "Extended-release tacrolimus : a review of its use in de novo kidney transplantation", Drugs, 74, pp.2053~2064 (2014)[DOI]
19. Patel P, "Formulation strategies for drug delivery of tacrolimus : an overview", Int J Pharm Investig, 2, pp.169~175 (2012)[DOI]
20. Nicolai S, "Hypersensitivity reaction to intravenous but not oral tacrolimus", Transplantation, 94, pp.e61~e63 (2012)[DOI]
21. Kang SY, "Intravenous tacrolimus and cyclosporine induced anaphylaxis : what is next?", Asia Pac Allergy, 5, pp.181~186 (2015)[DOI]
22. Ali SM, "Polyoxyl 60 hydrogenated castor oil free nanosomal formulation of immunosuppressant tacrolimus : pharmacokinetics, safety, and tolerability in rodents and humans", Int Immunopharmacol, 10, pp.325~330 (2010)[DOI]
23. Moreno Gonzales M, "Sublingual tacrolimus in liver transplantation : a valid option?", Transplant Proc, 48, pp.2102~2106 (2016)[DOI]
24. Pennington CA, "Sublingual tacrolimus as an alternative to oral administration for solid organ transplant recipients", Am J Health Syst Pharm, 72, pp.277~284 (2015)[DOI]
25. Staatz CE, "Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation", Clin Pharmacokinet, 43, pp.623~653 (2004)[DOI]
26. Christians U, "Mechanisms of clinically relevant drug interactions associated with tacrolimus", Clin Pharmacokinet, 41, pp.813~851 (2002)[DOI]
27. Hebert MF, "Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery", Adv Drug Deliv Rev, 27, pp.201~214 (1997)[DOI]
28. Schutte-Nutgen K, "Tacrolimus-pharmacokinetic considerations for clinicians", Curr Drug Metab, 19, pp.342~350 (2018)[DOI]
29. Lindholm A, "Therapeutic monitoring of cyclosporin--an update", Eur J Clin Pharmacol, 41, pp.273~283 (1991)[DOI]
30. Möller A, "The disposition of 14C-labeled tacrolimus after intravenous and oral administration in healthy human subjects", Drug Metab Dispos, 27, pp.633~636 (1999)
31. Araya AA, "Stat-Pearls" (2023), StatPearls Publishing
32. Kung L, "Immunophilins may limit calcineurin inhibition by cyclosporine and tacrolimus at high drug concentrations", Transplantation, 70, pp.327~335 (2000)[DOI]
33. Novartis Pharmaceuticals, "Sandimmune(cyclosporine)", Novartis Pharmaceuticals, ~ (2020)
34. Novartis Pharmaceuticals, "Neoral(cyclosporine modified)", Novartis Pharmaceuticals, ~ (2023)
35. Busuttil RW, "General guidelines for the use of tacrolimus in adult liver transplant patients", Transplantation, 61, pp.845~847 (1996)[DOI]
36. Astellas Pharma, "Prograf(tacrolimus)", Astellas Pharma, ~ (2022)
37. Astellas Pharma, "Astagraf XL", Astellas Pharma, ~ (2022)
38. McCormack PL, "Tacrolimus : in heart transplant recipients", Drugs, 66, pp.2269~2279 (2006)[DOI]
39. Ivulich S, "Clinical challenges of tacrolimus for maintenance immunosuppression post-lung transplantation", Transplant Proc, 49, pp.2153~2160 (2017)[DOI]
40. Brunet M, "Therapeutic drug monitoring of tacrolimuspersonalized therapy : second consensus report", Ther Drug Monit, 41, pp.261~307 (2019)[DOI]
41. Veloxis Pharmaceuticals, "Envarsus XR", Veloxis Pharmaceuticals, ~ (2020)
42. Liu Y, "MAPK phosphatases--regulating the immune response", Nat Rev Immunol, 7, pp.202~212 (2007)[DOI]
43. Barbarino JM, "PharmGKB summary : cyclosporine and tacrolimus pathways", Pharmacogenet Genomics, 23, pp.563~585 (2013)[DOI]
44. Atsaves V, "AP-1 transcription factors as regulators of immune responses in cancer", Cancers(Basel), 11, pp.1037~ (2019)[DOI]
45. Kraaijeveld R, "Inhibition of T helper cell differentiation by tacrolimus or sirolimus results in reduced B-cell activation : effects on T follicular helper cells", Transplant Proc, 51, pp.3463~3473 (2019)[DOI]
46. Henry ML, "Cyclosporine and tacrolimus(FK506) : a comparison of efficacy and safety profiles", Clin Transplant, 13, pp.209~220 (1999)[DOI]
47. Kamel M, "Tacrolimus confers lower acute rejection rates and better renal allograft survival compared to cyclosporine", World J Transplant, 6, pp.697~702 (2016)[DOI]
48. Krämer BK, "Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results", Nephrol Dial Transplant, 20, pp.968~973 (2005)[DOI]
49. Rath T, "Tacrolimus in transplant rejection", Expert Opin Pharmacother, 14, pp.115~122 (2013)[DOI]
50. Felldin M, "Rescue therapy with tacrolimus(FK 506)in renal transplant recipients--a Scandinavian multicenter analysis", Transpl Int, 10, pp.13~18 (1997)[DOI]
51. Jiang H, "Tacrolimus and cyclosporine differ in their capacity to overcome ongoing allograft rejection as a result of their differential abilities to inhibit interleukin-10 production", Transplantation, 73, pp.1808~1817 (2002)[DOI]
52. Busauschina A, "Cyclosporine nephrotoxicity", Transplant Proc, 36(2 Suppl), pp.229S~233S (2004)[DOI]
53. Bentata Y, "Tacrolimus : 20 years of use in adult kidney transplantation. What we should know about its nephrotoxicity", Artif Organs, 44, pp.140~152 (2020)[DOI]
54. Mayer AD, "Multicenter randomized trial comparing tacrolimus(FK506)and cyclosporine in the prevention of renal allograft rejection : a report of the European Tacrolimus Multicenter Renal Study Group", Transplantation, 64, pp.436~443 (1997)[DOI]
55. Anghel D, "Neurotoxicity of immunosuppressive therapies in organ transplantation", Maedica(Bucur), 8, pp.170~175 (2013)
56. Bechstein WO, "Neurotoxicity of calcineurin inhibitors : impact and clinical management", Transpl Int, 13, pp.313~326 (2000)[DOI]
57. Kälble T, "EAU guidelines on renal transplantation", Eur Urol, 47, pp.156~166 (2005)[DOI]
58. Konofaos P, "FK506 and nerve regeneration : past, present, and future", J Reconstr Microsurg, 29, pp.141~148 (2013)[DOI]
59. Kim YT, "Cotreatment effect of pulsed electromagnetic field(PEMF)with human dental pulp stromal cells and FK506 on the regeneration of crush injured rat sciatic nerve", Int J Neurosci, 125, pp.774~783 (2015)[DOI]
60. Udina E, "Bimodal dose-dependence of FK506 on the rate of axonal regeneration in mouse peripheral nerve", Muscle Nerve, 26, pp.348~355 (2002)[DOI]
61. Wang MS, "Comparative dosedependence study of FK506 and cyclosporin A on the rate of axonal regeneration in the rat sciatic nerve", J Pharmacol Exp Ther, 282, pp.1084~1093 (1997)
62. Lee M, "FK506 promotes functional recovery in crushed rat sciatic nerve", Muscle Nerve, 23, pp.633~640 (2000)[DOI]
63. Seixas SF, "Effect of tacrolimus and cyclosporine immunosuppressants on peripheral nerve regeneration : systematic review and metaanalysis", Rev Bras Ortop(Sao Paulo), 57, pp.207~213 (2022)[DOI]
64. Meirer R, "Effect of chronic cyclosporine administration on peripheral nerve regeneration : a dose-response study", Ann Plast Surg, 49, pp.96~103 (2002)[DOI]
65. Gold BG, "Immunophilin FK506-binding protein 52(not FK506-binding protein 12)mediates the neurotrophic action of FK506", J Pharmacol Exp Ther, 289, pp.1202~1210 (1999)
66. Devauchelle B, "First human face allograft : early report", Lancet, 368, pp.203~209 (2006)[DOI]
67. Lantieri L, "Repair of the lower and middle parts of the face by composite tissue allotransplantation in a patient with massive plexiform neurofibroma : a 1-year follow-up study", Lancet, 372, pp.639~645 (2008)[DOI]
68. Mele TS, "The use of mycophenolate mofetil in transplant recipients", Immunopharmacology, 47, pp.215~245 (2000)[DOI]
69. Kriss M, "Mycophenolate mofetil monotherapy in liver transplant recipients", Clin Transplant, 25, pp.E639~E646 (2011)[DOI]
70. Schmeding M, "Mycophenolate mofetil in liver transplantation--is monotherapy safe?", Clin Transplant, 20(Suppl 17), pp.75~79 (2006)[DOI]
71. Lassailly G, "Real life experience of mycophenolate mofetil monotherapy in liver transplant patients", Clin Res Hepatol Gastroenterol, 45, pp.101451~ (2021)[DOI]
72. Webster AC, "Target of rapamycin inhibitors(sirolimus and everolimus)for primary immunosuppression of kidney transplant recipients : a systematic review and metaanalysis of randomized trials", Transplantation, 81, pp.1234~1248 (2006)[DOI]
73. Moes DJ, "Sirolimus and everolimus in kidney transplantation", Drug Discov Today, 20, pp.1243~1249 (2015)[DOI]
74. Jorgenson MR, "Alternatives to immediate release tacrolimus in solid organ transplant recipients : when the gold standard is in short supply", Clin Transplant, 34, pp.e13903~ (2020)[DOI]
75. Klawitter J, "Everolimus and sirolimus in transplantation-related but different", Expert Opin Drug Saf, 14, pp.1055~1070 (2015)[DOI]
76. Zeng J, "Conversion from calcineurin inhibitors to mammalian target of rapamycin inhibitors in kidney transplant recipients : a systematic review and meta-analysis of randomized controlled trials", Front Immunol, 12, pp.663602~ (2021)[DOI]
77. Parlakpinar H, "Transplantation and immunosuppression : a review of novel transplant-related immunosuppressant drugs", Immunopharmacol Immunotoxicol, 43, pp.651~665 (2021)[DOI]
78. Kimzey AL, "Comprehensive toxicology. Vol. 11. Immune system toxicology", pp.399~427 (2018), Elsevier Science
79. Nair V, "Early conversion to belatacept after renal transplantation", Clin Transplant, 31, pp.e12951~ (2017)[DOI]
80. Bristol-Myers Squibb, "Belatacept", Bristol-Myers Squibb, ~ (2019)
81. El Hennawy H, "Belatacept rescue therapy of CNI-induced nephrotoxicity, meta-analysis", Transplant Rev(Orlando), 35, pp.100653~ (2021)[DOI]
82. Budde K, "Conversion from calcineurin inhibitor-to belatacept-based maintenance immunosuppression in renal transplant recipients : a randomized phase 3b trial", J Am Soc Nephrol, 32, pp.3252~3264 (2021)[DOI]
83. Mannon RB, "Avoidance of CNI and steroids using belatacept-results of the clinical trials in organ transplantation 16 trial", Am J Transplant, 20, pp.3599~3608 (2020)[DOI]
84. Grinyó JM, "Safety and efficacy outcomes 3 years after switching to belatacept from a calcineurin inhibitor in kidney transplant recipients : results from a phase 2 randomized trial", Am J Kidney Dis, 69, pp.587~594 (2017)[DOI]
85. Jones JW Jr, "Long-term survival of an extremity composite tissue allograft with FK506-mycophenolate mofetil therapy", Surgery, 126, pp.384~388 (1999)
86. Pushpakumar SB, "Clinical considerations in face transplantation", Burns, 36, pp.951~958 (2010)[DOI]
87. Diep GK, "The 2020 facial transplantation update : a 15-year compendium", Plast Reconstr Surg Glob Open, 9, pp.e3586~ (2021)[DOI]
88. Vyas K, "Facial transplantation", Facial Plast Surg Clin North Am, 30, pp.255~269 (2022)[DOI]
89. Leonard DA, "Immunobiology of face transplantation", J Craniofac Surg, 23, pp.268~271 (2012)[DOI]
90. Amini L, "CRISPR-Cas9-edited tacrolimus-resistant antiviral t cells for advanced adoptive immunotherapy in transplant recipients", Mol Ther, 29, pp.32~46 (2021)

관련 논문AI추천